Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Systematic Review Article

克唑替尼与化疗治疗ALK阳性NSCLC疗效及安全性的系统评价

卷 19, 期 1, 2019

页: [41 - 49] 页: 9

弟呕挨: 10.2174/1568009617666170623115846

价格: $65

摘要

前言：克列佐替尼于2011年被食品和药物管理局批准用于治疗间变性淋巴瘤激酶(ALK)阳性的非小细胞肺癌(NSCLC)。临床试验和回顾性研究的EW，以比较克唑替尼与化疗的疗效和安全性。 方法：从开始到2016年12月对电子数据库进行检索。临床试验和回顾性研究克列佐替尼和克列佐替尼与化疗治疗非小细胞肺癌的临床试验和回顾性研究是ELI。可互换的。主要结果为客观有效率(ORR)和疾病控制率(DCR)。 结果：9项研究(5项临床试验和4项回顾性研究)包括729例符合纳入标准的患者。卡唑替尼治疗1年的OS为77.1%，PFS为9.17个月.在ORR中，克唑替尼疗效优于化疗(OR：4.97，95%CI：3.16~7.83，P<0.00001，I2=35%)。DCR显示克唑替尼优于化疗(OR：3.42，95%CI：2.33)至5.01，P<0.00001，I2=0%。通过直接系统回顾，PR(部分反应)明显优于化疗(P<0.05)。CR(完全应答)无统计学意义卡唑替尼治疗组与化疗组比较，差异有显着性(P<0.05)。对于SD(稳定疾病)，化疗组疗效优于克唑替尼治疗组.共同的；共同的与克列佐替尼相关的ERSE事件有视力障碍、胃肠道副作用和肝转氨酶水平升高，而化疗时常见的不良反应是疲劳、NA。血液毒性。 结论：与化疗组相比，克唑替尼组客观有效率提高，疾病控制率提高。克左替尼治疗ALK阳性NSCLC患者的治疗方案。ALK抑制剂可能在其他由ALK或c-met基因突变驱动的癌症中具有潜在的应用前景。

关键词: 系统综述，Crizotinib，化疗，无瘤淋巴瘤激酶(ALK)，非小细胞肺癌(NSCLC)。

« Previous Next »
图形摘要

[1]
Shaw, A.T.; Engelman, J.A. ALK in lung cancer: past, present, and future. J. Clin. Oncol., 2013, 44, 1-7.
[2]
Steuer, C.E.; Ramalingam, S.S. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging tre-atment options. J. Cancer, 2014, 120(16), 2392-2402.
[3]
Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P.P.; Nambu, M.D. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 2007, 67(9), 4408-4417.
[4]
Bergethon, K.; Shaw, A.T.; Ou, S.H.I.; Katayama, R.; Lovly, C.M.; McDonald, N.T.; Massion, P.P.; Siwak-Tapp, C.; Gonzalez, A.; Fang, R.; Mark, E.J. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol., 2012, 30(8), 863-870.
[5]
Christensen, J.G.; Zou, H.Y.; Arango, M.E.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 2007, 6(12), 3314-3322.
[6]
Solomon, B.; Wilner, K.D.; Shaw, A.T. Current status of targeted therapy for anaplastic lymphoma kinase–rearranged non–small cell lung cancer. Clin. Pharmacol. Ther., 2014, 95(1), 15-23.
[7]
Pfizer Inc. EU Xalkori (crizotinib) summary of product characteristics. 2014.
[8]
Reck, M.; Popat, S.; Reinmuth, N.; De Ruysscher, D.; Kerr, K.M.; Peters, S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol 2014. 25(suppl_3), iii27-iii39.
[9]
Ettinger, D.S.; Akerley, W.; Borghaei, H.; Chang, A.C.; Cheney, R.T.; Chirieac, L.R.; D’Amico, T.A.; Demmy, T.L.; Ganti, A.K.; Govindan, R.; Grannis, F.W., Jr; Horn, L.; Jahan, T.M.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kong, F.M.; Kris, M.G.; Krug, L.M.; Lennes, I.T.; Loo, B.W., Jr; Martins, R.; O’Malley, J.; Osarogiagbon, R.U.; Otterson, G.A.; Patel, J.D.; Pinder-Schenck, M.C.; Pisters, K.M.; Reckamp, K.; Riely, G.J.; Rohren, E.; Swanson, S.J.; Wood, D.E.; Yang, S.C.; Hughes, M.; Gregory, K.M. NCCN (National Comprehensive Cancer Network). Non-small cell lung cancer. J. Natl. Compr. Canc. Netw., 2012, 10, 1236-1271.
[10]
Fukuoka, M.; Wu, Y.L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.S.; Sriuranpong, V.; Chao, T.Y.; Nakagawa, K.; Chu, D.T.; Saijo, N.; Duffield, E.L. Biomarker analyses and final overall survival results from a phase III,randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-celllung cancer in Asia (IPASS). J. Clin. Oncol., 2011, 29(21), 2866-2874.
[11]
American Cancer Society. Cancer Facts & Figures, 2013.http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/
[12]
Shaw, A.T.; Yeap, B.Y.; Solomon, B.J.; Riely, G.J.; Gainor, J.; Engelman, J.A.; Shapiro, G.I.; Costa, D.B.; Ou, S.H.I.; Butaney, M.; Salgia, R. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol., 2011, 12(11), 1004-1012.
[13]
Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crinó, L.; Ahn, M.J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; Wu, Y.L. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med., 2013, 368(25), 2385-2394.
[14]
Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.I.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; Varella-Garcia, M. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med., 2010, 363(18), 1693-1703.
[15]
Camidge, D.R.; Bang, Y.J.; Kwak, E.L.; Iafrate, A.J.; Varella-Garcia, M.; Fox, S.B.; Riely, G.J.; Solomon, B.; Ou, S.H.I.; Kim, D.W.; Salgia, R. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol., 2012, 13(10), 1011-1019.
[16]
Brosnan, E.M.; Weickhardt, A.J.; Lu, X.; Maxon, D.A.; Barón, A.E.; Chonchol, M.; Camidge, D.R. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer, 2013, 120(5), 664-674.
[17]
Berge, E.M.; Lu, X.; Maxson, D.; Barón, A.E.; Gadgeel, S.M.; Solomon, B.J.; Doebele, R.C.; Varella-Garcia, M.; Camidge, D.R. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non–small-cell lung cancer. Clin. Lung Cancer, 2013, 14(6), 636-643.
[18]
Solomon, B.J.; Mok, T.; Kim, D.W.; Wu, Y.L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; Iyer, S. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med., 2014, 371, 2167-2177.
[19]
Cui, S.; Zhao, Y.; Dong, L.; Gu, A.; Xiong, L.; Qian, J.; Zhang, W.; Niu, Y.; Pan, F.; Jiang, L. Is there a progression- free survival benefit of first- line crizotinib versus standard chemotherapy and second- line crizotinib in ALK- positive advanced lung adenocarcinoma? A retrospective study of Chinese patients. Cancer Med., 2016, 5(6), 1013-1021.
[20]
Zhang, Q.; Qin, N.; Wang, J.; Lv, J.; Yang, X.; Li, X.; Nong, J.; Zhang, H.; Zhang, X.; Wu, Y.; Zhang, S. Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma. Thorac. Cancer, 2016, 7, 3-8.
[21]
Ou, S.H.I.; Tong, W.P.; Azada, M.; Siwak‐Tapp, C.; Dy, J.; Stiber, J.A. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer, 2013, 119, 1969-1975.
[22]
Mellor, H.R.; Bell, A.R.; Valentin, J.P.; Roberts, R.R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci., 2011, 120, 14-32.
[23]
Ou, S.H.; Jänne, P.A.; Bartlett, C.H.; Tang, Y.; Kim, D.W.; Otterson, G.A.; Crinò, L.; Selaru, P.; Cohen, D.P.; Clark, J.W.; Riely, G.J. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann. Oncol., 2014, 25, 415-422.
[24]
Costa, D.B.; Shaw, A.T.; Ou, S.H.I.; Solomon, B.J.; Riely, G.J.; Ahn, M.J.; Zhou, C.; Shreeve, S.M.; Selaru, P.; Polli, A.; Schnell, P. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J. Clin. Oncol., 2015, 33(17), 1881-1888.
[25]
Solomon, B.J.; Cappuzzo, F.; Felip, E.; Blackhall, F.H.; Costa, D.B.; Kim, D.W.; Nakagawa, K.; Wu, Y.L.; Mekhail, T.; Paolini, J.; Tursi, J. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J. Clin. Oncol., 2016, 34(24), 2858-2865.
[26]
Gainor, J.F.; Tan, D.S.; De Pas, T.; Solomon, B.; Ahmad, A.; Lazzari, C.; De Marinis, F.; Spitaleri, G.; Schultz, K.; Friboulet, L.; Yeap, B.Y. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin. Cancer Res., 2015, 21(12), 2745-2752.
[27]
Dagogo-Jack, I.; Shaw, A.T. Crizotinib resistance: implications for therapeutic strategies. Ann. Oncol., 2016(Suppl. 3), iii42-iii50.
[28]
O’Bryant, C.L.; Wenger, S.D.; Kim, M.; Thompson, L.A. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann. Pharmacother., 2013, 47(2), 189-197.

Rights & Permissions Print Cite
Article Metrics
110
9
© 2024 Bentham Science Publishers | Privacy Policy